Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WAIT Study
2025-524182-25-00Phase 4Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 4 trial of semaglutide in Atrial fibrillation (AFib), obesity and Overweight, sponsored by Karolinska University Hospital. Primary endpoint: Freedom from atrial arrhythmias at 12 months post-ablation. Planned start Dec 2025; status: authorised.
02
Drugs
03
Conditions
Atrial fibrillation (AFib)obesityOverweight
Beyond the preview
Go deeper on 2025-524182-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524182-25-00.